Evidence map›Paper›PMID 35921286›Full record

ArticlePloS one2022

Human iPSC-derived astrocytes generated from donors with globoid cell leukodystrophy display phenotypes associated with disease.

Richard Lieberman, Leslie K Cortes, Grace Gao, Hyejung Park, Bing Wang, Patrick L Jones, R Bridge Hunter, John P Leonard, Robert H Barker

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Richard LiebermanLysosomal Storage and Metabolic Disease Cluster, Rare and Neurologic Disease Therapeutic Area, Sanofi, Framingham, MA, United States of America.ORCID 0000-0001-6662-5300
Leslie K CortesLysosomal Storage and Metabolic Disease Cluster, Rare and Neurologic Disease Therapeutic Area, Sanofi, Framingham, MA, United States of America.
Grace GaoLysosomal Storage and Metabolic Disease Cluster, Rare and Neurologic Disease Therapeutic Area, Sanofi, Framingham, MA, United States of America.
Hyejung ParkUS Early Development, Sanofi, Waltham, MA, United States of America.
Bing WangUS Early Development, Sanofi, Waltham, MA, United States of America.
Patrick L JonesLysosomal Storage and Metabolic Disease Cluster, Rare and Neurologic Disease Therapeutic Area, Sanofi, Framingham, MA, United States of America.
R Bridge HunterLysosomal Storage and Metabolic Disease Cluster, Rare and Neurologic Disease Therapeutic Area, Sanofi, Framingham, MA, United States of America.
John P LeonardLysosomal Storage and Metabolic Disease Cluster, Rare and Neurologic Disease Therapeutic Area, Sanofi, Framingham, MA, United States of America.
Robert H BarkerLysosomal Storage and Metabolic Disease Cluster, Rare and Neurologic Disease Therapeutic Area, Sanofi, Framingham, MA, United States of America.
Sanofi (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globoid cell leukodystrophy (Krabbe disease) is a fatal neurodegenerative, demyelinating disease caused by dysfunctional activity of galactosylceramidase (GALC), leading to the accumulation of glycosphingolipids including psychosine. While oligodendrocytes have been extensively studied due to their high levels of GALC, the contribution of astrocytes to disease pathogenesis remains to be fully elucidated. In the current study, we generated induced pluripotent stem cells (iPSCs) from two donors with infantile onset Krabbe disease and differentiated them into cultures of astrocytes. Krabbe astrocytes recapitulated many key findings observed in humans and rodent models of the disease, including the accumulation of psychosine and elevated expression of the pro-inflammatory cytokine IL-6. Unexpectedly, Krabbe astrocytes had higher levels of glucosylceramide and ceramide, and displayed compensatory changes in genes encoding glycosphingolipid biosynthetic enzymes, suggesting a shunting away from the galactosylceramide and psychosine pathway. In co-culture, Krabbe astrocytes negatively impacted the survival of iPSC-derived human neurons while enhancing survival of iPSC-derived human microglia. Substrate reduction approaches targeting either glucosylceramide synthase or serine palmitoyltransferase to reduce the sphingolipids elevated in Krabbe astrocytes failed to rescue their detrimental impact on neuron survival. Our results suggest that astrocytes may contribute to the progression of Krabbe disease and warrant further exploration into their role as therapeutic targets.

Indexed as

Induced Pluripotent Stem CellsLeukodystrophy, Globoid CellAnimalsAstrocytesDisease Models, AnimalGalactosylceramidaseHumansPhenotypePsychosineGalactosylceramidasePsychosine

Identifiers

PMID35921286
PMCPMC9348679
OpenAlexW4289637653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.